A highly effective vaccine that guards against the deadly Ebola virus could be available by 2018, says the World Health Organization. Trials conducted in Guinea, one of the West African countries most affected by an outbreak of Ebola that ended this year,
show it offers 100% protection. The vaccine is now being fast-tracked for regulatory approval. Manufacturer Merck has made 300,000 doses of the rVSV-ZEBOV vaccine available for use should Ebola strike. GAVI, the global vaccine alliance, provided $5m for the stockpile. Results, published in The Lancet medical journal, show of nearly 6,000 people receiving the vaccine, all were free of the virus 10 days later. In a group of the same size not vaccinated, 23 later developed Ebola. Only one person who was vaccinated had a serious side effect that the researchers think was caused by the jab. This was a very high temperature and the patient recovered fully. It is not known how well the vaccine might work in children since this was not tested in the trial. The director of British-based medical research institute the Wellcome Trust described the findings as “remarkable”. “Had a vaccine been available earlier in the Ebola epidemic, thousands of lives might have been saved,” Jeremy Farrar said. “We have to get ahead of the curve and make promising diagnostics, drugs and vaccines for diseases we know could be a threat in the future.” The trial was led by the World Health Organization (WHO), working with Guinea’s health ministry and international groups. The WHO’s Marie-Paule Kieny said the results could help combat future outbreaks. “While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless,” said Dr Kieny, the lead author of the study. Other drug companies are developing different Ebola vaccines that could be used in the future too.